RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsNew bioconjugates (i.e. bispecifics) could effectively pair ONCY's reovirus, with different polysaccharides resulting in increased trafficking tof revirus to the tumor cell surface and further facilitate pushing biologics and cancer therapy into the next generation of personalized/precision medicine that reovirus brings to the treatment of various cancers, including metastatic breast, pancreatic, GI, and anal cancers, for example.
One benefit involves the initial event in reovirus infection which is attachment to the terminal sialic and acid moieties on cell-surface polysaccharides of susceptible cancer cells, leaving normal cells alone, thus precluding the adverse by-stander effects that antibody-drug conjugates cause, and resulting in the 'black-box' warnings that the FDA imposed on ADCs like Enhertu in the treatment of breast cancer.
Many points in the reovirus life cycle rely on interations with tumor cell as host machinery. The use of cellular architecture by reovirus at two distint steps in the viral life cycle, namely reovirus evtry and egress, converage on virual manipulation of intracellualr vesicular and cytoskeletal trafficking systmes, as ONCY has alluded to in several investor presentations and fireside chats.